Lorigerlimab for pancreatic cancer with BRCA or PALB2 gene changes
Part of Cancer clinical trials.
This study tests a new drug called lorigerlimab (MGD019) in people with pancreatic cancer that has spread and has a specific genetic change (BRCA1, BRCA2, PALB2, RAD51C, or RAD51D) known to affect DNA repair. The drug aims to help the immune system fight the cancer. This might be an option if you have already tried platinum-based chemotherapy and your cancer has progressed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have pancreatic cancer that has spread to other parts of the body.
- You have a known genetic change (mutation) in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D that is likely to be harmful.
- You have had at least one round of platinum-based chemotherapy (like carboplatin or oxaliplatin) and your cancer got worse during or after that treatment.
- You have at least one tumor that can be biopsied safely, and you are willing to have a fresh biopsy.
- You have not had prior treatment with drugs that target PD-1 or PD-L1 (like pembrolizumab or nivolumab).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug for people with advanced solid tumors or lymphoma that has not responded to standard treatments and has a specific genetic change (loss of MTAP or CDKN2A genes). The drug is taken by mouth and may work by targeting cancer cells with this change.
This trial tests a new drug, lorigerlimab, for people with certain types of ovarian cancer or related cancers that have come back or not responded to treatment. The goal is to see if the drug can help shrink tumors or slow the disease.
This study tests a new combination of immunotherapy drugs for cervical cancer that has spread or returned. It aims to see if the treatment can shrink tumors and improve outcomes for people whose cancer is not curable with standard treatments.
This trial tests two drugs (vilastobart and retifanlimab) for people with advanced pancreatic cancer who have a specific genetic change in BRCA1, BRCA2, or PALB2. The goal is to see if this drug combination can help shrink tumors or slow their growth.
This trial tests a new drug for people with advanced pancreatic cancer that has grown despite at least one prior chemotherapy. The goal is to see if this drug can shrink tumors or slow the cancer, potentially giving patients more time.
This study tests a new drug (MRG004A) for advanced pancreatic cancer that has not responded to earlier treatments. The drug is given together with best supportive care (treatments to manage symptoms), and compared to a placebo (a dummy treatment) with best supportive care. The goal is to see if the new drug can slow down the cancer and help you live longer.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.